Title
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
Safety and Efficacy Evaluation of Umbilical Cord Mesenchymal Stem Cells Transcatheter Transplantation to Treat Left Ventricular Dysfunction After Acute Myocardial Infarction
Phase
Phase 1Lead Sponsor
Shanghai Life Science & TechnologyStudy Type
InterventionalStatus
Not yet recruitingIndication/Condition
Left Ventricular Dysfunction Acute Myocardial InfarctionIntervention/Treatment
UC-MSC ...Study Participants
40A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation
In this study, 40 patients with cardiac insufficiency after acute myocardial infarction were selected and randomly divided into umbilical cord MSCs transplantation treatment group and non-intervention control group to preliminarily observe the safety and effectiveness of MSCs cell transplantation treatment.
0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU, at the concentration of 2x10(7) cells/ml.
Routine treatment without catheter infusion
Inclusion Criteria: Patients with acute extensive anterior myocardial infarction were successfully treated with emergency interventional therapy within 12 hours after onset. LVEF was less than 0.35 by echocardiography 30 days after operation, scar area was more than 25% by MRI, and cardiac function was NYHA III-IV grade. Fully inform the purpose, method and possible side effects of the test, agree to the test, and sign an informed consent form; Good compliance, willing to take drugs and follow up according to the requirements of the plan; Life expectancy exceeds one year. Exclusion Criteria: Those who cannot tolerate cell therapy; Patients with severe hepatic and renal insufficiency (ALT>1.5 times the upper limit of normal value, Cr >1.5 times the upper limit of normal value); Patients with malignant tumors or extremely weak patients; Patients with severe infection; Patients who are expected to have the second coronary intervention or bypass grafting within 3 months; Patients with other serious systemic diseases and organ dysfunction; Patients with cardiogenic shock; Patients with hemorrhagic diseases; Researchers believe that anyone who is not suitable for inclusion